Join
Live feed
·
PRReleasevia Quantisnow
NextCure Inc. logo

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

ByQuantisnow·Wall Street's wire, on your screen.
NXTC· NextCure Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NXTC (NextCure Inc.) and more on Quantisnow.